IFR 128 BioSciences Gerland - Lyon Sud

U851 INSERM – UCBL – HCL

Team: APOPTOSIS and CD8 T cells MEMORY

Team leader: Jacqueline Marvel

Current project

Related Project

Team members

Publications

Thesis

Open position

Our team participate to different projects :

	Lenti-genesis
	Transgenic animals can be broadly defined as animals that contain recombinant DNA molecules in their genome that have been introduced by human intervention (Wall, 1996). Developmental studies and clinically relevant disease models are based on transgenic laboratory animals, most commonly the mouse. Microinjection of DNA is most widespread method for generating transgenic animals, but transgenesis rates achieved this way in higher mammals are low.
To address this longstanding problem, we used an alternative method: viral transgenesis (the use of recombinant viruses to deliver genes into the embryo). We have developped lentiviral vectors carrying a ubiquitously active promoter to deliver transgenes to mice embryos with the collaboration of different platform : - Plateau de Biologie Experimentale de la Souris (PBES) - Plateau de Vectorologie - Plateau d’Analyse Genetique Contact : Jacqueline Marvel more info

	EUMODIC European Mouse Disease Clinic
	Eumodic is an integrated project under the Sixth Framework Programme of the European Union. It’s a four-year program, which started in february 2007. Eumodic follows up the Eumorphia program.

EUMODIC is a first step towards tackling the need for large-scale phenotyping in the mouse and the comprehensive study of mammalian gene function and its role in disease.
The EUMODIC consortium is made up of 18 laboratories across Europe who are experts in the field of mouse functional genomic and phenotyping and have a track record of successful collaborative research in EUMORPHIA.
Primary phenotype assessment will be undertaken in four large-scale phenotyping centres. Then, a distributed network of centres with in depth expertise in a number of phenotyping domains will undertake more complex, secondary phenotyping screens and apply them to a subset of the mice which have shown interesting phenotypes in the primary screen.

A consortium of Lyon research teams and technical plates-forms referred as Ani.Rhône-Alpes will participate as secondary phenotyping center. Our teams participate at this secondary phenotyping. We will be specifically involved in 2 work packages : Immune response and Skeletomuscular

Contact : Sophia Djebali
more info about Eumodic

	Platine European platform of immunomonitoring
	PLATINE is a new project of European platform of immunomonitoring, certified by Lyonbiopôle. The main aim of this project is to identify, develop and validate new biomarkers of efficiency for new therapeutic molecules in the field of the oncology, the onco-haematology and infectious disease.
This project include the additional competence of 5 partners : - 3 industrial company : Innate Pharma, Transgene and ImmunIDTechnologie - 2 academic laboratory (INSERM) : Inserm U590 « Cytokines et Cancers » and U851 « immunité, infection et vaccination » - an hospital center : Centre Léon Bérard Platine project combines at the same time, conventional and strong techniques of immunomonitoring and innovative methods from their partners. The Inserm U851 target is to identify new candidate markers for specific cellular immune response using various pre-clinical experimental models. Contact : Stéphane Schicklin / Sophia Djebali more info about Platine

Partners :

 Mise à jour le 6 mars 2009